With data from a mid-stage trial showing weight loss of up to 12.3% at 28 weeks in patients treated with PF’3944, "Pfizer is moving full speed into obesity clinical development,” BMO Capital Markets ...
BREAKWATER trial Cohort 3 analysis demonstrated statistically significant and clinically meaningful improvement in ...
Program offers significant savings on over 30 brands spanning women’s health, migraine, arthritis, rare disease and moreAffirms Pfizer’s commitment to reduce drug costs for millions of Americans ...
The MarketWatch News Department was not involved in the creation of this content. -- VESPER-3 reinforces confidence in monthly dosing of PF-08653944 (MET-097i), including the potential for higher ...
Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call Tuesday, looking for any nugget of additional context.
Agence France-Presse on MSN
Pfizer shares drop on quarterly loss
Pfizer reported a quarterly loss Tuesday following a large write-down, denting shares as it confirmed 2026 financial targets with lower revenues. "Current financial guidance does not anticipate any ...
Barchart on MSN
Pfizer reports strong earnings outlook - unusual call options activity shows investors are bullish
Pfizer, Inc. (PFE) reported strong earnings and earnings guidance on Feb. 3. Large, unusual call option activity today, as ...
Pharmaceutical giant Pfizer (PFE) released its fourth quarter earnings results that topped Wall Street's expectations on its top and bottom lines. The stock is coming under some pressure on Tuesday ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results